Haemonetics Corp (HAE) is gearing up for another turning point as it hit the volume of 1.45 million

Haemonetics Corp (NYSE: HAE) on Tuesday, plunged -3.37% from the previous trading day, before settling in for the closing price of $71.29. Within the past 52 weeks, HAE’s price has moved between $69.29 and $97.97.

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 6.80%. The company achieved an average annual earnings per share of 15.92%. With a float of $49.67 million, this company’s outstanding shares have now reached $50.38 million.

Considering the fact that the conglomerate employs 3657 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 51.7%, operating margin of 14.19%, and the pretax margin is 11.67%.

Haemonetics Corp (HAE) Insider Activity

Observing investor behavior towards Medical Instruments & Supplies industry stocks is more important than anything else. The insider ownership of Haemonetics Corp is 1.11%, while institutional ownership is 112.04%. The most recent insider transaction that took place on Nov 11 ’24, was worth 565,692. Before that another transaction happened on Jul 26 ’24, when Company’s President, Global Hospital sold 4,312 for $91.15, making the entire transaction worth $393,039. This insider now owns 18,196 shares in total.

Haemonetics Corp (HAE) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.29 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 15.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.33% during the next five years compared to 17.09% growth over the previous five years of trading.

Haemonetics Corp (NYSE: HAE) Trading Performance Indicators

Haemonetics Corp (HAE) is currently performing well based on its current performance indicators. A quick ratio of 2.09 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.54. Likewise, its price to free cash flow for the trailing twelve months is 91.34.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.41, a number that is poised to hit 1.17 in the next quarter and is forecasted to reach 5.28 in one year’s time.

Technical Analysis of Haemonetics Corp (HAE)

Compared to the last year’s volume of 0.63 million, its volume of 0.88 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 9.67%. Additionally, its Average True Range was 2.85.

During the past 100 days, Haemonetics Corp’s (HAE) raw stochastic average was set at 0.91%, which indicates a significant decrease from 1.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.05% in the past 14 days, which was higher than the 34.67% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $80.59, while its 200-day Moving Average is $82.28. Nevertheless, the first resistance level for the watch stands at $71.01 in the near term. At $73.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $74.30. If the price goes on to break the first support level at $67.71, it is likely to go to the next support level at $66.53. Should the price break the second support level, the third support level stands at $64.42.

Haemonetics Corp (NYSE: HAE) Key Stats

Market capitalization of the company is 3.46 billion based on 50,224K outstanding shares. Right now, sales total 1,309 M and income totals 117,560 K. The company made 345,510 K in profit during its latest quarter, and 33,830 K in sales during its previous quarter.